Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation

Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation

The molecule “T cell immunoreceptor with immunoglobulin and ITIM domain,” or TIGIT, has recently received much attention as a promising target in the treatment of various malignancies. In spite of the quick progression of anti-TIGIT antibodies into clinical testing both as monotherapy and in combina...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit: Jin-Hwan Han, Mingmei Cai, Jeffery Grein, Samanthi Perera, Hongmei Wang, Mike Bigler, Roenna Ueda, Thomas W. Rosahl, Elaine Pinheiro, Drake LaFace, Wolfgang Seghezzi, Sybil M. Genther Williams
Materiálatiipa: Artihkal
Giella:English
Almmustuhtton: Frontiers Media S.A. 2020-10-01
Ráidu:Frontiers in Immunology
Fáttát:
TIGIT
FcγR
myeloid cells
combination cancer immunotherapy
costimulatory molecules
immune checkpoint blockade
Liŋkkat:https://www.frontiersin.org/article/10.3389/fimmu.2020.573405/full

Interneahtta

https://www.frontiersin.org/article/10.3389/fimmu.2020.573405/full

Geahča maid